Semaglutide EVOKE Plus (NCT04777409)

Overview

The Semaglutide EVOKE Plus trial (NCT04777409) is a Phase 3 equivalent clinical trial evaluating the efficacy and safety of oral semaglutide (14 mg once daily) in patients with early Alzheimer's disease. Sponsored by Novo Nordisk, this trial represents one of the largest ongoing AD therapeutic studies, enrolling approximately 1,840 participants across multiple international sites[@clinicaltrialsgov2026][@novo].

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for Type 2 diabetes and obesity. This trial tests the hypothesis that GLP-1 receptor activation can exert neuroprotective effects in Alzheimer's disease through multiple mechanisms, including reduced neuroinflammation, improved insulin signaling, and enhanced mitochondrial function[@salcedo2022][@zhang2020].

Trial Identifier: NCT04777409 Status: Active, not recruiting (as of March 2026) Start Date: 2021 Estimated Completion: 2025-2026 Phase: Phase 3 Enrollment: 1,840 participants Sponsor: Novo Nordisk A/S

Rationale: GLP-1 Receptor Agonism in Alzheimer's Disease

The Metabolic-Inflammatory Hypothesis

Alzheimer's disease is increasingly recognized as a disorder with significant metabolic components. Type 2 diabetes mellitus is a established risk factor for AD, and insulin resistance is commonly observed in the brains of AD patients. This has led to the "type 3 diabetes" hypothesis, which proposes that AD represents a form of brain-specific insulin resistance[@de2008].

Overview

The Semaglutide EVOKE Plus trial (NCT04777409) is a Phase 3 equivalent clinical trial evaluating the efficacy and safety of oral semaglutide (14 mg once daily) in patients with early Alzheimer's disease. Sponsored by Novo Nordisk, this trial represents one of the largest ongoing AD therapeutic studies, enrolling approximately 1,840 participants across multiple international sites[@clinicaltrialsgov2026][@novo].

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for Type 2 diabetes and obesity. This trial tests the hypothesis that GLP-1 receptor activation can exert neuroprotective effects in Alzheimer's disease through multiple mechanisms, including reduced neuroinflammation, improved insulin signaling, and enhanced mitochondrial function[@salcedo2022][@zhang2020].

Trial Identifier: NCT04777409 Status: Active, not recruiting (as of March 2026) Start Date: 2021 Estimated Completion: 2025-2026 Phase: Phase 3 Enrollment: 1,840 participants Sponsor: Novo Nordisk A/S

Rationale: GLP-1 Receptor Agonism in Alzheimer's Disease

The Metabolic-Inflammatory Hypothesis

Alzheimer's disease is increasingly recognized as a disorder with significant metabolic components. Type 2 diabetes mellitus is a established risk factor for AD, and insulin resistance is commonly observed in the brains of AD patients. This has led to the "type 3 diabetes" hypothesis, which proposes that AD represents a form of brain-specific insulin resistance[@de2008].

GLP-1 receptor agonists like semaglutide address multiple aspects of this metabolic dysfunction:

• Insulin sensitization: GLP-1R activation enhances insulin signaling in neuronal cells, improving glucose uptake and utilization
• Anti-inflammatory effects: GLP-1 agonists suppress pro-inflammatory cytokine production and microglial activation
• Mitochondrial protection: These agents help maintain mitochondrial function and reduce oxidative stress
• Synaptic support: GLP-1 signaling promotes synaptic plasticity and neurogenesis

GLP-1 Receptors in the Brain

GLP-1 receptors are expressed in multiple brain regions relevant to Alzheimer's disease, including the hippocampus (critical for memory), cortex, and basal forebrain. Activation of these receptors triggers intracellular signaling cascades that exert neuroprotective effects[@salcedo2022][@zhang2020]:

Previous Clinical Evidence

Phase 2 Liraglutide Trial (ELAD)

The Evidence for Liraglutide in Alzheimer's Disease (ELAD) trial was a landmark study evaluating liraglutide (another GLP-1 agonist) in patients with mild AD[@gejl2016]:

Key Findings:

• Liraglutide treatment for 12 months was well-tolerated
• Treatment group showed reduced decline in cerebral glucose metabolism
• Trends toward better cognitive outcomes, though not statistically significant
• Established safety profile for GLP-1 agonists in AD population

Preclinical Evidence

Multiple preclinical studies have demonstrated semaglutide's neuroprotective properties:

• Reduced amyloid-beta-induced neuronal death in vitro[@bomba2018]
• Improved cognitive performance in APP/PS1 transgenic mice[@pan2010]
• Decreased neuroinflammation in mouse models of AD[@liu2015]
• Enhanced hippocampal synaptic plasticity[@mcclean2014]

Trial Design

Study Type

Design: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 trial

Allocation: 1:1 randomization to semaglutide vs. placebo

Duration: 104 weeks (2 years) of treatment

Arms

| Arm | Intervention | Dosage |
|-----|--------------|--------|
| Semaglutide | Oral semaglutide | 14 mg once daily |
| Placebo | Oral placebo | Once daily |

Primary Endpoints

Cognitive Endpoint:

• Change from baseline to week 104 in ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognitive Subscale 13)

• Change from baseline to week 104 in ADCS-iADL (Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living)

Secondary Endpoints

Cognitive Measures:

• ADCOMS (Alzheimer's Disease Composite Score)
• MMSE (Mini-Mental State Examination)
• CDR (Clinical Dementia Rating)

• Plasma amyloid-beta (Aβ42/40 ratio)
• Plasma tau (p-tau181)
• Neurofilament light chain (NfL)
• CSF biomarkers (in subset)

• Adverse events (AEs)
• Serious adverse events (SAEs)
• Discontinuation rates
• Gastrointestinal events (most common with GLP-1 agonists)

Eligibility Criteria

Inclusion Criteria

• Age 55-85 years at screening
• Diagnosis of mild cognitive impairment (MCI) due to AD or mild dementia due to AD
• Confirmed amyloid positivity (PET or CSF)
• MMSE score 20-26 at screening
• CDR global score 0.5 or 1.0
• Stable acetylcholinesterase inhibitor and/or memantine regimen (if applicable) for ≥3 months
• Reliable study partner available

Exclusion Criteria

• Significant neurological disorder other than AD
• History of stroke or transient ischemic attack within 24 months
• Current diagnosis of major depression or bipolar disorder
• Type 1 diabetes or poorly controlled Type 2 diabetes (HbA1c >8.5%)
• History of pancreatitis
• History of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Contraindication to MRI
• Prior exposure to semaglutide or other GLP-1 agonists
• Participation in other interventional clinical trials within 12 months

Trial Sites

The EVOKE Plus trial is conducted at over 200 sites across North America, Europe, Asia, and Australia. Sites include major academic medical centers and specialized memory clinics.

Significance

The Semaglutide EVOKE Plus trial represents a critical test of the metabolic/inflammatory hypothesis of Alzheimer's disease. If positive, it could:

The trial results are expected in 2025-2026 and will be pivotal for the field of metabolic therapies in neurodegeneration.

Cross-References

• [GLP-1 Receptor Agonists in Neurodegeneration](/therapeutics/glp1-receptor-agonists) — Overview of the drug class
• [Neuroinflammation in Alzheimer's Disease](/mechanisms/neuroinflammation) — Mechanism of neuroinflammation in AD
• [Metabolic Dysfunction in Alzheimer's Disease](/mechanisms/brain-energy-metabolism) — Brain energy metabolism in AD

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References